CollPlant Biotechnologies Ltd. (CLGN): Price and Financial Metrics


CollPlant Biotechnologies Ltd. (CLGN): $11.53

0.69 (+6.37%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CLGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CLGN POWR Grades

  • CLGN scores best on the Sentiment dimension, with a Sentiment rank ahead of 92.84% of US stocks.
  • CLGN's strongest trending metric is Quality; it's been moving up over the last 40 days.
  • CLGN ranks lowest in Value; there it ranks in the 6th percentile.

CLGN Stock Summary

  • With a price/sales ratio of 218.11, COLLPLANT BIOTECHNOLOGIES LTD has a higher such ratio than 98.32% of stocks in our set.
  • Over the past twelve months, CLGN has reported earnings growth of -1,291.55%, putting it ahead of just 1.15% of US stocks in our set.
  • Revenue growth over the past 12 months for COLLPLANT BIOTECHNOLOGIES LTD comes in at -96.53%, a number that bests merely 0.93% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to CLGN, based on their financial statements, market capitalization, and price volatility, are VERU, SAGE, FUSN, TFFP, and SPCE.
  • CLGN's SEC filings can be seen here. And to visit COLLPLANT BIOTECHNOLOGIES LTD's official web site, go to www.collplant.com.

CLGN Valuation Summary

  • CLGN's price/earnings ratio is -7.7; this is 134.84% lower than that of the median Healthcare stock.
  • CLGN's EV/EBIT ratio has moved down 1 over the prior 61 months.

Below are key valuation metrics over time for CLGN.

Stock Date P/S P/B P/E EV/EBIT
CLGN 2023-01-30 228.3 3.5 -7.7 -5.8
CLGN 2023-01-27 261.3 4.0 -8.8 -6.9
CLGN 2023-01-26 225.6 3.5 -7.6 -5.7
CLGN 2023-01-25 199.8 3.1 -6.8 -4.9
CLGN 2023-01-24 200.4 3.1 -6.8 -4.9
CLGN 2023-01-23 201.3 3.1 -6.8 -4.9

CLGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CLGN has a Quality Grade of B, ranking ahead of 84.35% of graded US stocks.
  • CLGN's asset turnover comes in at 0.588 -- ranking 76th of 184 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows CLGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.588 0.844 0.227
2021-03-31 0.878 0.830 0.406
2020-12-31 0.517 0.511 -0.700
2020-09-30 0.508 0.492 -0.717
2020-06-30 0.215 0.120 -0.935
2020-03-31 0.203 0.165 -0.909

CLGN Price Target

For more insight on analysts targets of CLGN, see our CLGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $23.00 Average Broker Recommendation 1.5 (Moderate Buy)

CLGN Stock Price Chart Interactive Chart >

Price chart for CLGN

CLGN Price/Volume Stats

Current price $11.53 52-week high $14.77
Prev. close $10.84 52-week low $4.27
Day low $10.50 Volume 19,800
Day high $11.72 Avg. volume 26,333
50-day MA $8.33 Dividend yield N/A
200-day MA $8.10 Market Cap 127.82M

CollPlant Biotechnologies Ltd. (CLGN) Company Bio


CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants; VergenixSTR, a soft tissue repair matrix intended for treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.


CLGN Latest News Stream


Event/Time News Detail
Loading, please wait...

CLGN Latest Social Stream


Loading social stream, please wait...

View Full CLGN Social Stream

Latest CLGN News From Around the Web

Below are the latest news stories about COLLPLANT BIOTECHNOLOGIES LTD that investors may wish to consider to help them evaluate CLGN as an investment opportunity.

CollPlant Issues Letter to Shareholders

CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, is pleased to issue the following letter from its Chief Executive Officer, Yehiel Tal, to its shareholders.

Yahoo | January 24, 2023

CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives

CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced that it has successfully completed a large animal study for its recombinant human collagen (rhCollagen)-based 3D bioprinted regenerative breast implants, addressing the $2.5 billion global breast implant market. Supported by these promising results, the Company is planning to initiate a follow-up large animal study dur

Yahoo | January 4, 2023

CollPlant Enriches Portfolio of rhCollagen-Based Bioinks with Launch of Collink.3DTM 50L in Powder Form

CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced the launch of Collink.3DTM 50L, a recombinant human collagen (rhCollagen)-based bioink in a powder form for use in a wide range of 3D bioprinting applications, including drug discovery, drug screening, tissue testing as well as the development of transplantable tissues and organs.

Yahoo | January 3, 2023

Can you now get a good deal on CollPlant Biotechnologies Ltd.’s shares?

The share price of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) fell to $8.34 per share on Friday from $8.68. While CollPlant Biotechnologies Ltd. has underperformed by -3.92%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CLGN fell by -36.91%, with highs and lows ranging from $18.30 to $4.27, […]

US Post News | December 26, 2022

We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | December 12, 2022

Read More 'CLGN' Stories Here

CLGN Price Returns

1-mo 34.07%
3-mo 80.72%
6-mo 30.43%
1-year 21.50%
3-year 7.66%
5-year N/A
YTD 38.08%
2022 -48.96%
2021 51.90%
2020 88.95%
2019 35.71%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.856 seconds.